Top pharmaceutical companies in the world in 2017

Views & Analysis
Top pharmaceutical companies 2017

The rankings of the top pharmaceutical companies in the world in 2017 presented a mixed picture, with stability for some of the 25 largest firms as others saw their value fall.

Looking at recent research by GlobalData on the biggest pharma firms as listed by market capitalisation (see table below), the data and analytics company found just half of the top pharmaceutical companies achieved double digital growth.

Meanwhile, the value of five pharmaceutical companies fell in 2017 as Merck & Co, Celgene, GlaxoSmithKline (GSK), Allergan and Shire all saw their market capitalisation decline.

Janssen J&J Johnson and Johnson pharmaceutical companiesBut there was little change at the upper reaches of the ranks of the top pharmaceutical companies, as Johnson & Johnson, Roche and Pfizer retaining their top-three status, but Roche leapfrogging Pfizer into the number two slot.

Notably, all three took steps during 2017 to boost their oncology portfolios, with Pfizer’s $14 billion Medivation deal, Roche’s $1.7 billion acquisition of Ignyta and several purchases by J&J, including Actelion for $30 billion.

GlobalData’s listing of publicly-traded global pharma companies, based on a combination of its own analysis, annual reports and stock exchange filings, also found Vertex fared better than most, doubling its market cap to $40 billion in 2017.

During this time sales of its lead product Orkambi (ivacaftor/lumacaftor) rose 35% to reach $1.3 billion and blockbuster status, while Kalydeco (ivacaftor) was up 20% with sales of $845 million.

Abbott and AbbVie also increased their market cap by more than 50% in 2017, supported by their promising late-stage clinical pipelines. For AbbVie this includes its oral JAK1-selective inhibitor upadacitinib in moderate to severe rheumatoid arthritis and investigational interleukin-23 (IL-23) inhibitor risankizumab in moderate to severe chronic plaque psoriasis. Meanwhile, Abbott was buoyed by the performance of its Alinity portfolio of diagnostic systems.

Novo Nordisk and Bayer entered the top 10 this year after crossing the $1 billion market capitalisation value, primarily driven by rising sales.

Top pharmaceutical companiesAmal George, lead analyst at GlobalData, explained: ‘’Novo Nordisk grew sales from the diabetes and obesity care categories through its Tresiba, Victoza and Saxenda brands, while Bayer benefited from the de-consolidation of its adhesive manufacturing subsidiary Covestro and increased sales from its core pharma brands Xarelto, Eylea, Mirena and Xofigo.’’

George added: ‘’It’s easy to see why investors have confidence in the sector. Collectively the top 25 pharma companies reported a healthy average operating margin of 22% which increased to 25% for the top 10.’’

Finally, looking to the future, the top companies continued to invest well in R&D, with an overall R&D/ Sales average of 18.2% (once you remove Vertex’s whopping 96.5%).

Top pharmaceutical companies by market cap in 2017

Company Market Cap ($m) 2017 Rank 2016 Rank
Johnson & Johnson (J&J) 387,235 1 1
Roche 217,746 2 3
Pfizer 217,029 3 2
Novartis 205,443 4 4
AbbVie 160,026 5 8
Merck & Co 154,859 6 5
Novo Nordisk 137,396 7 12
Amgen 133,117 8 6
Sanofi 111,433 9 7
Bayer 105,904 10 13
Abbott 102,556 11 20
Gilead Sciences 102,076 12 11
Bristol-Myers Squibb 101,248 13 10
Eli Lilly 94,760 14 15
GlaxoSmithKline 90,159 15 9
AstraZeneca 88,528 16 16
Celgene 83,054 17 14
Biogen 71,132 18 18
Allergan 58,418 19 17
Merck KGaA 48,696 20 22
CSL 47,439 21 21
Shire 45,113 22 19
Regeneron Pharmaceuticals 39,607 23 23
Vertex Pharmaceuticals 39,455 24 33
Takeda Pharmaceutical 39,285 25 25

Source: GlobalData, annual reports and stock exchange filings